Broussardhoppe0094

The molecular and pharmacological manipulation of the endogenous redox system is a promising therapy to limit myocardial damage after a heart attack; however, antioxidant therapies have failed to fully establish their cardioprotective effects, suggesting that additional factors, including antioxidant system interactions with other molecular pathways, may alter the pharmacological effects of antioxidants. Since gender differences in cardiovascular disease (CVD) are prevalent, and sex is an essential determinant of the response to oxidative stress, it is of particular interest to understand the effects of sex hormone signaling on the activity and expression of cellular antioxidants and the pharmacological actions of antioxidant therapies. In the present review, we briefly summarize the current understanding of testosterone effects on the modulation of the endogenous antioxidant systems in the CV system, cardiomyocytes, and the heart. We also review the latest research on redox balance and sexual dimorphism, with particular emphasis on the role of the natural antioxidant system glutathione (GSH) in the context of myocardial infarction, and the pro- and antioxidant effects of testosterone signaling via the androgen receptor (AR) on the heart. Finally, we discuss future perspectives regarding the potential of using combing antioxidant and testosterone replacement therapies to protect the aging myocardium. V.INTRODUCTION Radiologic assessment of interbody fusion (IF) is controversial; thin-slice CT is the present gold standard despite artifacts due to the metal implant that hinder interpretation. The present study aimed to assess the contribution of MRI in IF assessment after instrumented posterior lumbar interbody fusion (PLIF) using tantalum intervertebral implants. The study hypothesis was that fusion following PLIF can be assessed on MRI. selleck chemical MATERIALS AND METHOD A single-center retrospective study included 52 single-level PLIF procedures (42 for degenerative disc disease and 10 for isthmic spondylolisthesis) using 2 tantalum intervertebral cages without interbody bone graft. Fusion was assessed at 1 year on static and dynamic X-ray and on MRI with a dedicated protocol. Two senior osteoarticular radiologists screened frontal and sagittal MRI slices for continuous cancellous interbody bridges. Consolidation was considered acquired (grade I) in case of continuous bridges on at least 2 successive frontal or sagittalidge between endplates being a requirement. LEVEL OF EVIDENCE IV. INTRODUCTION Intervertebral implants increase stability and improve results in lumbar interbody fusion (LIF). The aim of the present study was to assess clinical and radiological results of posterior lumbar interbody fusion (PLIF) using a tantalum intervertebral implant without associated interbody bone graft. MATERIEL AND METHODS A single-center retrospective study included 52 cases of single-level PLIF, using 2 tantalum intervertebral cages, without interbody bone graft 42 for degenerative disc disease, 10 for isthmic spondylolisthesis. Minimum follow-up was 2 years. Clinical assessment used a visual analog (pain) scale (VAS), the Oswestry Disability Index (ODI) and the Roland Morris (RM) scale. Tantalum osseointegration and intersegment mobility were assessed on static and dynamic X-ray. RESULTS Forty-nine patients were included, with a mean 55months' follow-up (range, 25-74months). VAS, ODI and RM scores showed significant improvement at last-follow-up, at 4, 30 and 28 points respectively. There was no mechanical failure on static X-ray; all patients had less than 5° mobility on dynamic X-ray at last follow-up. DISCUSSION PLIF with tantalum intervertebral implant without interbody bone graft provided satisfactory clinical and radiological results at medium-term follow-up. The present findings showed reliable primary stability and osseointegration of the tantalum implant. LEVEL OF EVIDENCE IV. Vaccines have prevented and nearly eliminated several deadly diseases, yet they face skepticism from the public. One potential driver of vaccine skepticism is how people process event frequencies such as rare adverse reactions to vaccines. Misestimations may distort the perceived risks of vaccinating. The current study examined how vaccine skepticism is related to accuracy in event frequency processing. In Experiment 1, participants (n = 158) estimated the frequencies of several vital statistics (e.g., 'How many people die per year in the U.S. from emphysema?'). Higher levels of vaccine skepticism were associated with lower accuracy in frequency estimation and over-estimation of rare events. In Experiment 2 (n = 109), we again found that vaccine skepticism was negatively associated with vital statistic estimation accuracy but not for emotionally neutral or positive events. These results suggest that vaccine skepticism may arise from basic individual differences in processing events associated with mortality or negative affect. The present study was conducted to monitor sales activity and immunogenicity of commercial H9N2 vaccines produced in Korea from 2007 to 2017. Recorded sales of H9N2 vaccine were around 671 million doses, with 10 million doses sold in 2007, rising to a peak of 93 million doses in 2016, with a slight fall in 2017. Multivalent combined vaccines made up around 90% of all vaccine sales, and around 30% of all vaccines were distributed by regional governments for free. The regional vaccination rate was the highest in Gyeonggi and Chungnam, respectively with proportional to the population of layer and breeder chickens. There have been no cases of field infection since 2009. The mean antibody titer was 5.82 log2 across the study period. Our results suggest that continuous genetic monitoring of H9N2 viruses circulating in the field and updating the vaccine seed strain periodically are necessary in order to control H9N2 outbreaks. BACKGROUND Japanese encephalitis (JE) virus is the leading vaccine-preventable cause of encephalitis in Asia. For most travelers, JE risk is very low but varies based on several factors, including travel duration, location, and activities. To aid public health officials, health care providers, and travelers evaluate the worth of administering/ receiving pre-travel JE vaccinations, we estimated the numbers-needed-to-treat to prevent a case and the cost-effectiveness ratios of JE vaccination for U.S. travelers in different risk categories. METHODS We used a decision tree model to estimate cost per case averted from a societal and traveler perspective for hypothetical cohorts of vaccinated and unvaccinated travelers. Risk Category I included travelers planning to spend ≥1 month in JE-endemic areas, Risk Category II were shorter-term ( less then 1 month) travelers spending ≥20% of their time doing outdoor activities in rural areas, and Risk Category III were all remaining travelers. We performed sensitivity analyses including examining changes in cost-effectiveness with 10- and 100-fold increases in incidence and medical treatment costs.